<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838602</url>
  </required_header>
  <id_info>
    <org_study_id>2012-760</org_study_id>
    <nct_id>NCT02838602</nct_id>
  </id_info>
  <brief_title>Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors</brief_title>
  <acronym>ETOILE</acronym>
  <official_title>Transnational Randomized Study Comparing Carbon Ions Therapy Versus Conventional Radiotherapy - Including Protontherapy - for the Treatment of Radioresistant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a transnational prospective randomized trial comparing definitive carbon ion therapy&#xD;
      versus photon or combined photon and protontherapy as standard treatment for unresectable or&#xD;
      macroscopically uncompleted resected radioresistant tumors. Eligible tumors are axial&#xD;
      chordoma (except of base of skull), adenoid cystic carcinoma of head and neck (except of&#xD;
      trachea) and sarcomas of any site (except chondrosarcoma of the skull base), non previously&#xD;
      irradiated and without pre-planned surgery or chemotherapy after the clinical trial&#xD;
      procedure. Randomization is balanced 1 for 1. Patients of the experimental arm are treated in&#xD;
      carbon ions centers in Europe and patients of the standard arm are treated in France in their&#xD;
      closest participating radiotherapy center. An accrual of 250 patients is needed and an&#xD;
      absolute difference of 20% of relapse free survival at five years is awaited. The main&#xD;
      endpoint is the progression free survival at five years. The trial is supported by the French&#xD;
      program of clinical research and the national health insurance. Two associated studies are&#xD;
      carried out: a radiobiological one looking for radioresistance markers in the sarcomas&#xD;
      biopsies, and the second one is about medico economics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2017</start_date>
  <completion_date type="Anticipated">December 23, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 5 years or loss of follow-up</time_frame>
    <description>Starting point for PFS measurement is the randomization date</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grades of the CTCAE-V4.02 classification</measure>
    <time_frame>up to 5 years or loss of follow-up</time_frame>
    <description>Tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D questionnaire</measure>
    <time_frame>up to 5 years or loss of follow-up</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local progression free survival</measure>
    <time_frame>up to 5 years or loss of follow-up</time_frame>
    <description>takes account of the local progression of the tumor in the planning target volume (PTV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastases free survival</measure>
    <time_frame>up to 5 years or loss of follow-up</time_frame>
    <description>takes account of any site of relapse outside of the PTV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years or loss of follow-up</time_frame>
    <description>delay of death of any cause accounted starting from randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma</condition>
  <arm_group>
    <arm_group_label>Carbon ions therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radical and exclusive carbon ions radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical radiotherapy by Xrays and / or protons</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon ions therapy</intervention_name>
    <description>External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center</description>
    <arm_group_label>Carbon ions therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Advanced external radiotherapy by Xrays or protons</intervention_name>
    <description>Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy</description>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  No severe comorbidity, life expectancy above 10 years&#xD;
&#xD;
          -  Unresectable or inoperable or R2 resection of the tumor&#xD;
&#xD;
          -  Eligible radioresistant tumor according to the limitative list as following:&#xD;
&#xD;
               -  adenoid cystic carcinoma of head and neck (larynx and trachea excluded)&#xD;
&#xD;
               -  soft tissue sarcoma&#xD;
&#xD;
               -  pleomorphic rhabdomyosarcoma only (alveolar and embryonal forms excluded)&#xD;
&#xD;
               -  retroperitoneal sarcoma under condition of technical feasibility (movement)&#xD;
&#xD;
               -  osteosarcoma of any grade and localisation (Ewing excluded)&#xD;
&#xD;
               -  chondrosarcoma (except of skull base) OMS grade &gt;= 2&#xD;
&#xD;
               -  chordoma axial skeleton or pelvis (except of skull base)&#xD;
&#xD;
               -  angiosarcoma&#xD;
&#xD;
          -  Absence of epidermal invasion (a hypodermic invasion is accepted with fixity of&#xD;
             cutaneous plan but not true epidermal permeation)&#xD;
&#xD;
          -  Larger volume to be irradiated (PTV) less than 25 cm&#xD;
&#xD;
          -  ECOG Performance Status ≤ 2 or Karnovsky index ≥ 60&#xD;
&#xD;
          -  no pregnancy of possibility of pregnancy during the treatment&#xD;
&#xD;
          -  having an health insurance&#xD;
&#xD;
          -  signature of a written informed consent&#xD;
&#xD;
          -  validation of the randomization criteria: namely, a carbon ions therapy indication&#xD;
             assessed by the medical team of a hadrontherapy center and able to by treated within&#xD;
             two month from registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complete macroscopic or microscopic surgical resection (R0 or R1)&#xD;
&#xD;
          -  previous irradiation in the volume to be treated&#xD;
&#xD;
          -  metastatic disease&#xD;
&#xD;
          -  disease not candidate to a curative approach (example accelerated progressive&#xD;
             diseaseresistant to nay medical treatment especially for sarcoma)&#xD;
&#xD;
          -  any contra-indication to undergo a radiation therapy by Xray or particle therapy&#xD;
&#xD;
          -  planned surgery or chemotherapy to take place after completion of radiotherapy&#xD;
             (example : absence of enough space between an organ risk and the target volume (at&#xD;
             least 5 mm) except the possibility of a spacer insertion)&#xD;
&#xD;
          -  planned surgery or chemotherapy after radiotherapy&#xD;
&#xD;
          -  Presence in the target volume of metallic material which cannot be removed (carbon&#xD;
             fibres matreial authorized)&#xD;
&#xD;
          -  history of concomittant (except in situ cervix carcinoma; or any cured basocellular&#xD;
             cutaneous cancer tor any cured cancer with no sign of relapse during 5 years))&#xD;
&#xD;
          -  impossible follow-up over 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal POMMIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal POMMIER, MD</last_name>
    <phone>(0)4 78 78 51 66</phone>
    <phone_ext>+33</phone_ext>
    <email>pascal.pommier@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude KRZISCH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claude KRZISCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CLCC François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliette THARIAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juliette THARIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dinu STEFAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine LEROUGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard GERY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura MOISE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine NOAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques BALOSSO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CRLCC Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fanny MARTIN</last_name>
    </contact>
    <investigator>
      <last_name>Fanny MARTIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel LAPEYRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica MIROIR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CRLCC GF Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles TRUC, MD</last_name>
      <phone>03.80.73.75.18</phone>
    </contact>
    <investigator>
      <last_name>Gilles TRUC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noémie VULQUIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David THIBOUW, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline AMOYAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, Hôpital A. Michallon, CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille, Olivier VERRY, MD</last_name>
      <phone>04.76.76.54.35</phone>
    </contact>
    <investigator>
      <last_name>Camille, Olivier VERRY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie VILLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques BALOSSO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole IRIART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Violaine BRUN-BARONNAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CRLCC Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier MIRABEL, MD</last_name>
      <phone>03.20.29.55.98</phone>
    </contact>
    <investigator>
      <last_name>Xavier MIRABEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaëlle MOUTTET-AUDOUARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abel CORDOBA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier LIEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David PASQUIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CRLCC Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal POMMIER, MD</last_name>
      <phone>(0)4 78 78 51 66</phone>
      <phone_ext>+33</phone_ext>
      <email>pascal.pommier@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal POMMIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Pierre SUNYACH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent GREGOIRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CRLCC Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence MOUREAU-ZABOTTO, MD</last_name>
      <phone>04.91.22.36.37</phone>
    </contact>
    <investigator>
      <last_name>Laurence MOUREAU-ZABOTTO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, Institut Régional du Cancer Montpellier, ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre BOISSELIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre BOISSELIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle de radiothérapie, Centre Antoine-Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander FALK, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexander FALK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme DOYEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Yves BONDIAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen BENEZERY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CHU Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Loïc FEUVRET</last_name>
      <phone>01.42.17.81.71</phone>
    </contact>
    <investigator>
      <last_name>Loïc FEUVRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie, site Hôpital de Paris et site d'Orsay (Centre de protonthérapie)</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rémi DENDALE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rémi DENDALE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire ALAPETITE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, Hôpital de Haut Lévêque, CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles DUPIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Charles DUPIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huchet AYMERI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CRLCC Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie SERVAGI-VERNAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphanie SERVAGI-VERNAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joël CASTELLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joël CASTELLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CRLCC René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Augustin MERVOYER, MD</last_name>
      <phone>02.40.67.99.30</phone>
    </contact>
    <investigator>
      <last_name>Augustin MERVOYER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia WIAZZANE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirtz</name>
      <address>
        <city>St Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas MAGNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amel REHAILIA-BLANCHARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grégoire PIGNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, CRLCC Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges NOEL, MD</last_name>
      <phone>03.88.25.24.71</phone>
    </contact>
    <investigator>
      <last_name>Georges NOEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire du cancer de Toulouse - Oncopole, Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DUCASSOU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne DUCASSOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne LAPRIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martine DELANNES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, Institut de Cancérologie de Lorraine Alexis Vautrin</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume VOGIN, MD</last_name>
      <phone>03.83.59.84.27</phone>
    </contact>
    <investigator>
      <last_name>Guillaume VOGIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie RENARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie, Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile LE PECHOUX, MD</last_name>
      <phone>01.42.11.42.11</phone>
    </contact>
    <investigator>
      <last_name>Cécile LE PECHOUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie BOLLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carbon ions therapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>radioresistant tumors</keyword>
  <keyword>cancer</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

